A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia | MicrobiomeTrials← Back to trialsNCT02255435
A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2015-01-31Est. Completion: 2019-10-31
Enrollment target: 172 participants Locations- UCLA, Los Angeles, California, United States
- University of Florida - Neurology, Gainesville, Florida, United States
- USF Ataxia Research Center, Tampa, Florida, United States
- Emory University Hospital - Neurology, Atlanta, Georgia, United States
- University of Iowa Stead Family Children's Hospital, Iowa City, Iowa, United States
- Ohio State University - Neurology, Columbus, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Murdoch Childrens Research Institute, Parkville, Victoria, Australia
- Medical University Innsbruck, Innsbruck, Austria
- Neurological Institute Carlo Besta, Milan, Italy
- University College of London, London, United Kingdom
Other microbiome trials you might be interested in
Friedreich Ataxia
An open label study designed to evaluate the safety, PK, PD, and clinical effects of long-term daily administration of C…
Los Angeles, United StatesEst. completion Jan 2027
Friedreich Ataxia
In this study, researchers will learn more about BIIB141, also known as omaveloxolone or SKYCLARYS®. This drug has been …
Philadelphia, United StatesEst. completion Jun 4, 2030